Literature DB >> 24863726

Comparative study of elbow disorders in young high-performance gymnasts.

J Dexel1, K Marschner1, H Beck1, I Platzek2, S Wasnik1, M Schuler3, A Nasreddin2, P Kasten1.   

Abstract

The study aimed to investigate the prognosis of osteochondral affection (e.g., osteochondritis dissecans (OCD), cartilage lesions, fractures and bone edema in the elbows of high-performance gymnasts (n=30) compared to prognosis results with athletes not undergoing excessive stress on the upper extremity (n=29). The study also tested a novel isotropic 3D-FSE-sequence (CUBE) technique as an early diagnostic modality. Standard protocol was used to conduct the MRI examinations, which were then compared to results from the CUBE - sequence. The gymnast group (p=0.012) presented a significantly higher prevalence of complaints in the elbow joint compared to the other athlete group. Furthermore, osteochondral lesions in MRIs appeared more frequently in the group of gymnasts (n=10, 33%, p=0.033), including 7 cases (23%) of OCD. In the control athlete group 2 asymptomatic cases of OCD and one case of bone edema were detected. The MRI investigation with the CUBE - sequence showed similar results as the standard MRI protocol in terms of the diagnosis sensitivity. The current study indicates that juvenile gymnasts are at a higher risk for osteochondral lesions of the elbow than athletes without excessive stress on the upper extremities. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 24863726     DOI: 10.1055/s-0034-1371835

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  2 in total

Review 1.  Osteochondritis dissecans of the elbow.

Authors:  Ryan W Churchill; Julianne Munoz; Christopher S Ahmad
Journal:  Curr Rev Musculoskelet Med       Date:  2016-06

2.  Elbow arthroscopy in children and adolescents: analysis of outcome and complications.

Authors:  Jörg Nowotny; Sebastian Löbstein; Achim Biewener; Guido Fitze; Philip Kasten
Journal:  Eur J Med Res       Date:  2018-09-15       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.